Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test
Skeletal safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains uncharted, with emerging evidence suggesting a divergence between mono- and dual-agonist therapies. GLP-1RA monotherapy appears bone-neutral, with modest or no adverse effects on bone mineral density (BMD), whilst dual a...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI AG
2026-07-01
|
| Series: | Diagnostics |
| Assuntos: | |
| Acceso en liña: | https://www.mdpi.com/2075-4418/16/13/2128 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|